Medicare Compliance & Reimbursement - 2015 Issue 6
In other news
Subscribe or sign in to view the full article.
Article Overview
This brief article explains a payer’s reminder about evaluation and management documentation when drug therapy requires intensive monitoring for toxicity. It is relevant to coders, auditors, and clinicians who document medical decision-making, and it focuses on general compliance expectations, documentation support, and the distinction between a patient being on a medication versus actively managing and monitoring it.
Why This Topic Matters
It helps readers understand that risk points in evaluation and management coding must be supported by documented physician management and monitoring, which can affect code selection and audit readiness.
What You Will Learn
- How the topic of intensive drug monitoring fits into evaluation and management risk documentation.
- Why payer documentation support matters when reflecting drug-related toxicity risk.
- What type of record evidence a payer says should be present for this level of risk.
- How the article frames the difference between medication use and active monitoring.
Who Should Read This
- Medical coders
- Coding auditors
- Physicians and advanced practitioners
- Compliance staff
- Revenue cycle professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com